Table 3 Recent clinical trials for PARP, ATR, DNA-PK, WEE1, and CHK1 inhibitors: monotherapy and combination therapy
From: Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Target | Agent | Intervention | Cancer Type | Phase | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|
PARP | Olaparib | Olaparib | Breast and ovarian cancer | IV | NCT04330040 |
Olaparib + Paclitaxel + Durvalumab | Advanced gastric cancer | II | NCT03579784 | ||
Olaparib + Abiraterone | Prostate cancer | III | NCT03732820 | ||
Olaparib + Durvalumab | Bladder cancer | II | NCT03534492 | ||
Olaparib + Temozolomide | Colorectal cancer | II | NCT04166435 | ||
Niraparib | Niraparib | Pancreatic cancer | II | NCT03601923 | |
Niraparib + Osimertinib | Lung cancer | I | NCT03891615 | ||
Niraparib + Dostarlimab | Ovarian cancer | III | NCT03602859 | ||
Niraparib + MGD013 | Gastric and gastroesophageal junction cancer | I | NCT04178460 | ||
Niraparib + Dostarlimab | Cervix cancer | II | NCT04068753 | ||
Rucaparib | Rucaparib | Endometrial cancer | II | NCT03617679 | |
Rucaparib + Nivolumab | Biliary tract cancer | II | NCT03639935 | ||
Rucaparib + Radiotherapy | Breast cancer | I | NCT03542175 | ||
Rucaparib + Copanlisib | Prostate cancer | I | NCT04253262 | ||
Rucacparib + Enzalutamide + Abiraterone | Prostate cancer | I | NCT04179396 | ||
Talazoparib | Talazoparib | Leukemia | I | NCT03974217 | |
Talazoparib + Avelumab | Breast cancer | I | NCT03964532 | ||
Talazoparib + Radiotherapy | Gynecologic cancer | I | NCT03968406 | ||
Talazoparib + ASTX727 | Breast cancer | I | NCT04134884 | ||
Talazoparib + Avelumab | Lung cancer | II | NCT04173507 | ||
Talazoparib + Axitinib | Kidney cancer | I/II | NCT04337970 | ||
Talazoparib + Atezolizumab | Lung cancer | II | NCT04334941 | ||
Talazoparib + Gedatolisib | Breast cancer | II | NCT03911973 | ||
ATR | Berzosertib (M6620) | Berzosertib + Radiotherapy | Lung cancer | I | NCT02589522 |
Berzosertib + Radiotherapy | Breast cancer | I | NCT04052555 | ||
Berzosertib + Topotecan | Lung cancer | I/II | NCT02487095 | ||
Berzosertib + Topotecan Hydrochloride | Lung cancer | II | NCT03896503 | ||
Berzosertib + Carboplatin + Docetaxel | Prostate cancer | II | NCT03517969 | ||
AZD6738 | AZD6738 + Radiotherapy | Advanced solid tumors | I | NCT02223923 | |
AZD6738 + Olaparib | Gynecologic cancer | II | NCT04065269 | ||
AZD6738 + Olaparib + Durvalumab | Breast cancer | II | NCT03740893 | ||
AZD6738 + Acalabrutinib | Chronic lymphocytic leukemia | I/II | NCT03328273 | ||
AZD6738 + Durvalumab | Biliary tract cancer | II | NCT04298008 | ||
BAY1895344 | BAY1895344 | Advanced solid tumors | I | NCT03188965 | |
BAY1895344 + Pembrolizumab | Advanced solid tumors | I | NCT04095273 | ||
BAY1895344 + Niraparib | Ovarian cancer | I | NCT04267939 | ||
M4344 | M4344 + Niraparib | Ovarian cancer | I | NCT04149145 | |
M4344 + Carboplatin | Advanced solid tumors | I | NCT02278250 | ||
DNA-PK | CC-115 | CC-115 | Advanced solid tumors | I | NCT01353625 |
CC-115 + Enzalutamide | Prostate cancer | I | NCT02833883 | ||
AZD7648 | AZD7648 + Olaparib + Pegylated Liposomal Doxorubicin | Advanced solid tumors | I/II | NCT03907969 | |
M9831 (VX-984) | M9831 | Advanced solid tumors | I | NCT02644278 | |
Nedisertib (M3814) | Nedisertib + Pegylated Liposomal Doxorubicin Hydrochloride | Ovarian cancer | I | NCT04092270 | |
Nedisertib + Avelumab + Radiotherapy | Hepatobiliary cancer | I/II | NCT04068194 | ||
Nedisertib + Avelumab + Radiotherapy | Advanced solid tumors | I | NCT03724890 | ||
WEE1 | Adavosertib (AZD1775) | Adavosertib | Advanced solid tumors | I | NCT01748825 |
Adavosertib | Advanced solid tumors | II | NCT03253679 / NCT03284385 | ||
Adavosertib + Gemcitabine + Cisplatin + Carboplatin | Advanced solid tumors | I | NCT00648648 | ||
Adavosertib + Olaparib | Ovarian, primary peritoneal, and fallopian tube cancer | II | NCT03579316 | ||
Adavosertib + Olaparib + AZD6738 | Breast cancer | II | NCT03330847 | ||
Adavosertib + Irinotecan | Advanced solid tumors | I/II | NCT02095132 | ||
Adavosertib + Cisplatin + Radiotherapy | Cervical, vaginal, and uterine cancer | I | NCT03345784 | ||
Adavosertib + Temozolomide + Radiotherapy | Glioblastoma | I | NCT01849146 | ||
CHK1 | SRA737 | SRA737 | Advanced solid tumors | I/II | NCT02797964 |
SRA737 + Gemcitabine + Cisplatin | Advanced solid tumors | I/II | NCT02797977 | ||
Prexasertib (LY2606368) | Prexasertib | Advanced solid tumors | I | NCT01115790 | |
Prexasertib | Lung cancer | II | NCT02735980 | ||
Prexasertib | Breast, ovarian, and prostate cancer | II | NCT02203513 | ||
Prexasertib + Cisplatin + Cetuximab + Radiotherapy | Head and neck cancer | I | NCT02555644 |